Stem cell shot aims to mend brittle bones in older women

NCT ID NCT06949137

Ongoing Disease control Sponsor: HELP Therapeutics Co., Ltd. Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This early-stage trial is testing a new stem cell treatment called HMM910 in 9 postmenopausal women with osteoporosis who are at high risk of breaking a bone. The stem cells are given through an IV drip. The main goal is to see if the treatment is safe and tolerable, not yet to prove it works. If it passes safety checks, larger studies could explore whether it actually strengthens bones.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: human umbilical cord-derived mesenchymal stem cells (HMM910)
What this could lead to: If safe and effective, this could point toward a new treatment to strengthen bones and reduce fracture risk in postmenopausal women with osteoporosis.
What could go wrong: This is a very early Phase 1 trial with only 9 participants, so it is primarily testing safety, not effectiveness. The stem cell approach may not improve bone health and could cause unexpected side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for OSTEOPOROSIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

bone fracture osteoporosis postmenopausal osteoporosis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

OSTEOPOROSIS OSTEOPOROSIS IN POST-MENOPAUSAL WOMEN

Contacts and locations

Locations

HELP Therapeutics

Nanjing, Jiangsu, 210000, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.